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MiR-142-3p is a RANKL-dependent 
inducer of cell death in osteoclasts
Jezrom B. Fordham1, Katherine Guilfoyle2,†, Afsar Raza Naqvi1 & Salvador Nares1
MicroRNA are small, non-coding, single-stranded RNAs that are estimated to regulate ~60% of the 
human genome. MiRNA profiling of monocyte-to-osteoclast differentiation identified miR-142-3p 
as a miRNA that is significantly, differentially expressed throughout osteoclastogenesis. Enforced 
expression of miR-142-3p via transient transfection with miR-142-3p mimic inhibited cell-to-cell contact 
and fusion, decreased protein kinase C alpha expression, and ultimately reduced cell viability. miR-
142-3p was also identified as significantly differentially expressed during monocyte-to-macrophage 
differentiation and overexpression of miR-142-3p prevented their conversion to osteoclasts. 
Furthermore, the inhibitory effect of miR-142-3p on osteoclastogenesis extended to the conversion 
of a third osteoclast precursor cell type- dendritic cells. These results demonstrate miR-142-3p to 
be a negative regulator of osteoclastogenesis from the 3 main precursor cell types: monocytes, 
macrophages and dendritic cells. Importantly, decreased survival was dependent upon both miR-142-3p 
expression and RANK-signaling, with no harmful effects detected in the absence of this combination. 
As such, miR-142-3p represents a novel target for the selective removal of osteoclasts by targeting of 
osteoclastogenic pathways.
Dysregulated osteoclast (OC) function is a pathological component in a wide range of diseases affecting bone, 
such as osteoporosis, osteopetrosis, and metastatic breast cancer invasion of bone. As such, defining the regula-
tory processes coupled to OC development and function are of great therapeutic interest. Significant progress 
has been made in elucidating the cellular and molecular components governing bone metabolism; however, the 
impact of epigenetic regulation on OC development and function is not fully understood.
MicroRNAs (miRNA) have emerged as key players in the post-transcriptional regulatory mechanism of gene 
expression. MiRNA represent small, non-coding, single-stranded RNAs that regulate a plethora of cellular pro-
cesses1, and previous studies involving the silencing of DGCR8 and Dicer (essential for miRNA synthesis) have 
confirmed the importance of miRNA for osteoclastogenesis2. The importance of miRNA in OC differentiation 
and function is also evidenced by decreased activation of the OC transcription factors c-fos, PU.1, MITF and 
NFATc1 when DGCR8, Dicer or Ago2 (essential factors for miRNA homeostasis) are silenced2. To date, few 
miRNAs have been identified that regulate OC differentiation. However, an increasing body of evidence clearly 
indicate that miRNAs are operative at the commitment stage of osteoclastogenesis3.
Protein kinase C alpha (PKCα ) is one of several serine/threonine kinases that regulate important cellular 
functions including cell differentiation, apoptosis, and LPS signaling4. PKC-dependent pathways have been 
reported to play a key role in RANKL-induced OC differentiation, expression of OC-specific genes, and OC func-
tion5. Pharmacological inhibition of PKCα significantly reduces several hallmarks of osteoclastogenesis, includ-
ing decreased cell size, a lower average number of nuclei per OC, and the average ratio of cell area per nucleus6. 
Functionally, PKCα inhibition reduces the ability of OC to resorb bone4.
To date only a few miRNAs have been reported to target PKCα  including miR-200b7, miR-2038, 
pre-miR-24-29, and miR-15a10. However, these reports highlight miRNA targeting of PKCα during carcinogene-
sis/metastasis but not during normal bone metabolism. Previously, we have demonstrated miR-142-3p mediated 
inhibition of MΦ and DC phagocytosis via direct regulation of PKCα 11. Here we identify downregulation of miR-
142-3p as a requirement for monocyte-to-OC differentiation, as well as macrophage and DC conversion to OC.
1Department of Periodontics, University of Illinois at Chicago, Chicago, Illinois, USA. 2University of North Carolina 
at Chapel Hill, School of Dentistry, Department of Periodontics, 385 S. Columbia St., Chapel Hill, NC 27599, USA. 
†Present Address: Sarasota Periodontics, 450 Maple Ave, Sarasota Springs, NY 12866-5507, USA. Correspondence 
and requests for materials should be addressed to S.N. (email: snares@uic.edu)
received: 11 December 2015
Accepted: 07 April 2016
Published: 26 April 2016
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 6:24980 | DOI: 10.1038/srep24980
Results
MiRNA profiling during osteoclastogenesis reveals differential expression of novel miRNAs. 
Human CD14+ monocytes were isolated from healthy human donors and differentiated into OC using a com-
bination of recombinant human (rh) M-CSF and sRANKL, or macrophages by the addition of M-CSF alone. 
Representative images of monocytes (day 0), macrophages (day 7) and osteoclasts (TRAP stained, day 9) are 
presented in Fig. 1A. Osteoclastogenesis was confirmed by quantification of average number of nuclei per cell 
(Fig. 1B) and ability to digest collagen (Fig. 1C). Total RNA was collected at days 1, 3, 6, and 12 of differentiation 
and miRNA profiling was performed by microarray. An expression analysis of variance over time was performed 
and heat maps showing the relative expression level of the top 30 differentially expressed miRNAs are shown in 
Fig. 2 (OC differentiation is shown in Fig. 2A; macrophage differentiation in Fig. 2B). Analysis was performed 
using the complete-linkage method together with the euclidean distance measure. miRNAs identified as dif-
ferentially expressed during osteoclastogenesis included novel miRNAs such as miR-142-3p, as well miRNAs 
known to be involved in osteoclastogenesis- for example miR-223. Expression of miR-142-3p over time for OC 
(left) and macrophage (right) is presented in Fig. 2C. Inserts are validations of microarray results performed 
by RT-PCR. A total of 143 and 117 miRNAs were identified as significantly (ANOVA; p = < 0.05) differentially 
expressed during OC and macrophage differentiation, respectively (Fig. 2D). A total of 50 miRNAs were unique 
to OC differentiation, 25 miRNAs were unique to macrophage differentiation, and 93 miRNAs were present in 
both groups (Fig. 2D). Analysis of the direction of expression change revealed that miRNA downregulation was 
slightly favored in both processes (Fig. 2E).
Overexpression of miR-142-3p inhibits monocyte to OC differentiation. The functional signif-
icance of miR-142-3p expression during osteoclastogenesis was assessed using transient transfection methods 
to introduce miR-142-3p mimic, inhibitor, or control mimic (miRNA mimic possessing no interaction with any 
human 3′ UTR) to differentiating cultures. Cells were transfected at day 2 with miR-142-3p mimic, inhibitor, or 
control mimic. As previously reported, our transfection efficiency for these cells was approximately 90%11,12. OC 
cultures overexpressing miR-142-3p displayed greatly reduced clustering and fusion events relative to untreated, 
control mimic, or miR-142-3p inhibitor, at day 4 of culture. (Fig. 3A, top). Red lines highlight areas of significant 
cell-cell contact that is an immediate precursor to fusion. By day 9, OC cultures overexpressing miR-142-3p 
Figure 1. Phenotypic confirmation of monocyte-to-osteoclast and monocyte-to-macrophage 
differentiation. Human CD14+ monocytes were cultured in the presence of M-CSF and sRANKL, or M-CSF 
only. (A) Representative images of monocytes (day 0), macrophages (day 7) and OC (day 9; TRAP stained). (B) 
Average number of nuclei per cell for M-CSF + sRANKL (filled bars) and M-CSF only (empty bars) cultures 
over time. (C) Collagen degradation of M-CSF + sRANKL (filled bar) and M-CSF only (open bar) cultures over 
time. Data are presented as mean and SD, or representative images, from 4 biological donors. *p < 0.05 relative 
to monocyte (day 0) controls. P values were calculated using the Student’s t-test.
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contained far fewer cells and displayed a reduced number of multi-nucleated cells (Fig. 3A, bottom). There was a 
trend for greater clustering, fusion and higher average number of nuclei per cell in miR-142 inhibitor transfected 
cells, but this was not statistically significant (data not shown). Cell viability was assessed by MTS assay and this 
demonstrated a miR-142-3p mimic-dependent increase in cell death; however, this effect was only present from 
day 6 onwards, indicating that the reduced ability to cluster and fuse observed at day 4 was not due to reduced 
cell number (Fig. 3B, left). Furthermore, this decrease in viability was not present in the corresponding control 
cells in which sRANKL was omitted, demonstrating that increased cell death was sRANKL dependent (Fig. 3B, 
right). This is consistent with our previously reported effects of miR-142-3p overexpression/knock-down during 
monocyte-to-macrophage differentiation, in which we described no significant alteration of cell viability in the 
presence of M-CSF, GM-CSF, or GM-CSF plus IL-4 signaling12.
miR-142-3p mediated down-regulation of PKCα expression contributes to reduced OC survival. 
Day 2 differentiating OC were transfected with miR-142-3p mimic, inhibitor, or control mimic and PKCα protein 
and mRNA levels were assessed on day 6 and day 4, respectively. Results were normalized to GAPDH expression 
for both assays. Cultures transfected with miR-142-3p mimic displayed reduced PKCα at the level of mRNA and 
protein (Fig. 4A,B, respectively). Day 2 differentiating OC were also transfected with siRNA for PKCα or control 
siRNA. OC cultures transfected with PKCα siRNA displayed reduced size (Fig. 3C), reduced viability (Fig. 3D) 
and reduced average nuclei per cell (Fig. 3E).
miR-142-3p expression prevents the generation of OC from macrophage and DC. Human 
CD14+ monocytes were differentiated into macrophages using M-CSF, or into DC using GM-CSF and IL-4, as 
described previously11,12. These cells displayed all the phenotypic properties of macrophages and (immature) DC 
by day 7 of culture11,12. Day 7 cultures were left untransfected or transfected with miR-142-3p mimic, miR-142-3p 
inhibitor, or control mimic. 18 hrs later culture media was substituted for OC-differentiating media (RPMI, 
M-CSF+ sRANKL). At day 11, cultures combining transfection with control mimic or miR-142-3p inhibitor and 
Figure 2. miRNA profiling of monocyte to osteoclast differentiation. Human CD14+ monocytes were 
cultured in the presence of M-CSF+ sRANKL, or M-CSF only, and total RNA was isolated at day 0, 1, 3, 6 & 
12. (A) Heat map diagram of hierarchical clustering of samples and relative miRNA expression (top 30) for 
OC differentiation. (B) Heat map diagram of hierarchical clustering of samples and relative miRNA expression 
(top 30) for macrophage differentiation. (C) Expression of miR-142-3p over time for OC (left) and macrophage 
(right) as identified by microarray (main) and RT-PCR (insert). (D) Venn diagram of significantly differentially 
expressed miRNAs identified during monocyte-to-osteoclast and monocyte-to-macrophage differentiation. 
(E) Bar chart comparing the total number of upregulated (open bar) and downregulated (filled bar) miRNAs in 
both groups. Data are presented as mean and SD from 4 biological donors. P values were calculated by ANOVA 
and adjusted using the Benjamini Hochberg method.
www.nature.com/scientificreports/
4Scientific RepoRts | 6:24980 | DOI: 10.1038/srep24980
OC-differentiating conditions displayed increased size, and in the case of MΦ to OC conversion, the presence of 
giant cells (highlighted by white arrows) (Fig. 5A). In contrast, cultures combining transfection with miR-142-3p 
mimic and OC-differentiating conditions displayed very few cells (Fig. 5A). Assessment of cell viability from day 
8 to day 11 by MTS assay revealed a miR-142-3p mimic-dependent, sRANKL-dependent decrease in viability 
from day 9 through to day 11 (Fig. 5B). Validation of the protocol for MΦ and DC conversion to OC was assessed 
by collagen digest. At 14 days, untransfected macrophage and DC cultures cultured in OC-differentiating condi-
tions from day 8 displayed OC-like morphology and possessed the ability to degrade collagen (Fig. 5C; MΦ > OC 
& DC > OC bars). Cultures maintained in the absence of OC-differentiating conditions did not significantly 
degrade collagen (Fig. 5C; MΦ & DC bars).
Discussion
Osteoclasts are giant, multi-nucleated cells central to bone remodeling, being uniquely equipped for resorp-
tion and acting in concert with bone-forming osteoblasts to regulate bone mass. We profiled miRNA expres-
sion during monocyte-to-OC differentiation and found 143 miRNAs that were differentially expressed over 
time. These included miRNAs, such as miR-223, whose role in osteoclastogenesis has been well-characterized13, 
as well as novel miRNAs only identified due to advances in microarray technology, such as miR-4732-5p. 
Over a third of these miRNAs were specific to monocyte-to-osteoclast differentiation, being absent from 
monocyte-to-macrophage differentiation. The majority of miRNAs identified by profiling of monocyte-to-OC & 
monocyte-to-macrophage differentiation were similarly regulated in both groups. This is unsurprising given the 
nature of these processes, which include a common precursor cell, the presence of M-CSF signaling, and the same 
commitment to increased cell size and viability.
Figure 3. Increased cell death of osteoclast precursors by overexpression of miR-142-3p. Human CD14+ 
monocytes were cultured in the presence of M-CSF and sRANKL, or M-CSF only. Cultures were left untreated 
or transfected with miR-142-3p mimic, miR-142-3p inhibitor, or control mimic at day 2. (A) Brightfield images 
of differentiating osteoclasts (M-CSF and sRANKL) were taken at day 4 (top) and images of cells stained with 
Hoescht (nuclei; blue) and MitoTracker (mitochondria, red) were taken at day 9 (bottom). Red lines highlight 
areas of significant cell-cell contact. (B) Viability of M-CSF plus sRANKL, and M-CSF only, cultures assessed 
at different time-points by MTS assay, relative to untransfected cells. Filled black squares represent miR-142-3p 
mimic transfected cells, filled grey squares represent miR-142-3p inhibitor transfected cells, and empty circles 
represent control mimic transfected cells. Data are presented as mean and SD, or representative images, from 5 
biological donors. *p < 0.05 relative to untreated control cells. P values were calculated using the Student’s t-test.
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The identification of previously reported miRNAs, such as miR-223, provides further support both for their 
role in osteoclastogenesis, and for the validity of the novel miRNAs identified, such as miR-142-3p. miR-223 has 
been reported to regulate osteoclastogenesis by modulation of PU.1, NFI-A and M-CSFR circuitry, including 
c-Fos and CREB14, and while miR-142-3p is not predicted to target any of these, we show that miR-142-3p sim-
ilarly regulates osteoclastogenesis. This occurs via a mechanism that includes the targeting of PKCα , reduced 
cell-to-cell contact and fusion, and reduced cell viability. This phenomenon is RANKL-dependent and extends to 
macrophage and DC conversion to OC.
PKC is a well-established promoter of osteoclastogenesis. PKC stimulates RANKL expression in osteoblasts/
stromal cells and PKC inhibitors reduce OC differentiation and function15. miR-142-3p expression is significantly 
downregulated over the first 3 days of monocyte-to-OC differentiation with diminished expression maintained 
from day 3 through to day 12. This pattern was also present in the control group of monocyte-to-macrophage 
differentiation. We have previously reported miR-142-3p expression to be similarly decreased during 
monocyte-to-DC differentiation. Here we show miR-142-3p to be a negative regulator of both de novo and 
‘second-hand’ osteoclastogenesis, and postulate that such an effect is likely to be more efficacious (with regards 
to therapy) than a single-pathway approach to targeted modulation. Furthermore, while the fact that increased 
miR-142-3p expression correlates with increased cell death may be considered a weakness, we believe this must be 
tempered by the observation that it is RANKL-dependent. Monocyte-to-macrophage differentiation performed 
using the same conditions, but in the absence of sRANKL, demonstrated no such decrease in cell viability. Also, 
miR-142-3p mimic transfected macrophages or DCs were not adversely affected when exposed to M-CSF in the 
absence of sRANKL. Thus, in this context, miR-142-3p may be considered a RANKL-dependent inducer of cell 
death.
Figure 4. Phenotype and PKCα expression in osteoclast cultures transfected with miR-142-3p mimic or 
PKCα siRNA. Human CD14+ monocytes were cultured in the presence of M-CSF and sRANKL. (A) Cultures 
were left untreated or transfected with miR-142-3p mimic, miR-142-3p inhibitor, or control mimic. PKCα 
expression was assessed by qRT-PCR at day 4, or (B) by western blot at day 6. (C) Cultures were left untreated 
or transfected with PKCα siRNA, or control siRNA, at day 2. Images of cells stained with Hoescht (nuclei; blue) 
and LysoTracker (lysosomes, green) taken at day 9. (D) Viability of cultures at day 9 assessed by MTS assay. 
Expression is relative to untransfected controls. (E) Average number of nuclei per cell of cultures transfected 
with PKCα siRNA, control siRNA, or untransfected. Data are presented as mean and SD, or representative 
images, from 3 biological donors. *p < 0.05 relative to untreated control cells. P values were calculated using the 
Student’s t-test.
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While we have demonstrated the direct effect on PKCα by miR-142-3p, it is likely that other interactions 
may contribute to our findings. A number of studies have indicated an important role for the PKC pathway in 
osteoclastogenesis. PKC exists in multiple isoforms including α , β , δ , ε , ζ , θ , ι and λ variants. These isoforms dis-
play tissue-specific expression profiles and they are believed to possess common and independent mechanisms 
of function. Multiple PKC isoforms, including α , β , δ , ε and ζ , have been shown to be expressed during OC 
formation16. The pattern of expression of these isoforms has been reported to ‘flip’ during the related processes 
of monocyte-to-macrophage and monocyte-to-DC and this has been linked to the decreased propensity for cell 
death that accompanies monocyte commitment to differentiation. Previously, we reported an inverse correlation 
of miR-142-3p with PKCα mRNA levels and confirmed PKCα as a novel target of miR-142-3p11. PKCα signaling 
has also been shown to regulate apoptosis via altered expression of apoptosis-related genes, such as BCL2 and 
BCL2L1. These two molecules are also predicted targets of miR-142-3p and future work will provide insight into 
the contribution of miR-142-3p targeting of PKCα relative to its targeting of components downstream of PKCα 
signaling. Future work will also include screening the miRNAs identified here for their possible regulation of PKC 
isoforms.
Osteoclastogenesis requires cytoskeletal rearrangement including reorganization of the microtubule network 
and polarization of the actin network17. Osteoclastogenesis is also regulated by PKCα expression and this mol-
ecule is known to mediate signaling pathways that result in cytoskeletal rearrangement18,19. Overexpression of 
miR-142-3p inhibited cell-to-cell contact, clustering and fusion events, a property that we believe is attributed to 
reduced PKCα -mediated rearrangements of the microtubule and actin networks; however, this does not provide 
a rationale for the induction of cell death that we observed. We postulate that the observed decrease in PKCα 
Figure 5. Inhibition of macrophage and DC conversion to OC with miR-142-3p overexpression. Human 
CD14+ monocytes were cultured in the presence of M-CSF or GM-CSF plus IL-4 for differentiation into 
macrophages and DC, respectively. Macrophage and DC were transfected at day 7 with miR-142-3p mimic, 
miR-142-3p inhibitor, or control mimic, and culture conditions were substituted for OC-differentiating 
conditions. (A) Representative images of macrophage and DC at day 7, at day 11 with transfection and 
OC-differentiating conditions, and day 11 negative controls (control mimic transfected, absence of OC-
differentiating conditions). Cells were stained using MitoTracker (mitochondria, red). (B) Viability of 
macrophage-to-OC and DC-to-OC cultures from day 8 to day 11 assessed by MTS assay. (C) Collagen 
degradation of macrophage-to-OC and DC-to-OC cultures (untransfected) assayed at day 14. Data are 
presented as mean and SD, or representative images, from 3 biological donors. *p < 0.05 relative to untreated 
control cells. P values were calculated using the Student’s t-test.
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results in decreased expression of anti-apoptotic factors downstream of PKCα , which are known to include BCL2 
and BCR-ABL20,21. Our bioinformatic analysis has also revealed several potential interactions of miR-142-3p 
with BCL2 family members, including BCL2 and BCL2L1, as well as signaling molecules upstream of the PKCα 
pathway, such as phospho-inositide 3 kinase (PI-3K). The relative direct and indirect contributions of miR-142-3p 
target regulation on the observed phenotype will be interrogated. Given the promiscuity of miRNA-3′ UTR inter-
actions, and the predilection of miRNAs for regulating biology at the network level rather than single target 
modulation, we would anticipate the identification of multiple interactions that together explain the phenotypic 
effect described in this article.
Materials and Methods
Primary human monocyte isolation and OC generation. Freshly prepared buffy coats were collected 
from healthy donors (n ≥ 3) (Sylvan N. Goldman Oklahoma Blood Institute), CD14+ monocytes were obtained 
by density gradient centrifugation and magnetic bead isolation as described previously11,12. Briefly, PMBCs were 
purified using Ficoll PaqueTM (GE Healthcare) based density centrifugation. PBMCs were incubated with mag-
netically labeled CD14 beads (Miltenyi Biotech) according to manufacturer’s instructions. Monocyte purity and 
viability was > 95%, as determined by flow cytometry. For OC differentiation, monocytes were plated at 4 × 106/
ml in RPMI supplemented with penicillin (100U/ml) and streptomycin (100 μ g/ml). After 2 hours the media was 
substituted with media containing 10% FBS (Life Technologies), recombinant human M-CSF (50 ng/mL) and 
recombinant human sRANKL (100 ng/mL; both from PeproTech). Media was replaced every 72 hours.
For monocyte derived macrophage (mD-Mϕ ) differentiation, monocytes were plated at a density of 2 × 106/ml 
in DMEM, supplemented with penicillin (100 U/ml), streptomycin (100 μ g/ml), and gentamicin (50 μ g/ml). 
After 2 h, the media were substituted with media containing 10% heat-inactivated FBS (Life Technologies, 
Grand Island, NY, USA) and rhM-CSF (50 ng/ml; PeproTech, Rocky Hill, NJ, USA). For monocyte derived DC 
(mD-DC), monocytes were cultured in RPMI 1640, supplemented with rhGM-CSF (1000 U/ml) and rhIL-4 
(500 U/ml; both from PeproTech). Media were replaced every 72 h. At day 7, cells were harvested and differen-
tiation confirmed by flow cytometric analysis of CDw93, CD68, CD209, CD1a, CD11b, and CD11c expression. 
Additional confirmation of mD-Mϕ & mD-DC phenotype can be found in our previous publications11,12. For 
macrophage and DC conversion to OC, media was replaced with the same OC-differentiating medium described 
above with replenishment every 72 hrs.
OC staining and microscopy. Differentiation was assessed by staining cells for tartrate resistant acid phos-
phatase activity and number of nuclei (Hoescht, Invitrogen). Lysosomes and mitochondria were stained using 
LysoTracker and MitoTracker, respectively (Invitrogen). For fluorescent imaging, the EVOS® FL Cell Imaging 
System (Life Technologies) was used. TRAP staining was performed at 37 C using 10 mg Naphtol AS-MX phos-
phate, 1 mL dH2O, 0.2M sodium acetate solution, 0.2M acetic acid solution, 0.3M sodium tartrate, 0.1M ace-
tate buffer and TRAP buffer (pH = 5). Modified Giemsa stain (Romanowsky stain variant) was purchased as 
Diff-Quik (Polysciences, Inc.). Multi-nucleated cells were counted using software supplied as part of the imaging 
system. In brief, cells were cultured in 96-well plates, the center of each well aligned directly above the objec-
tive turret, and a 50 μ m × 50 μ m grid overlaid using the imaging software. Nuclei and cells present within (in 
whole or in part) an area of 1600 μ m2 were tagged and the average number of nuclei per cell was calculated from 
counts provided by the software. For quantification each sample was run as technical replicates with the average 
representing the value for the biological replicate. Analysis was performed on the averages from four biological 
replicates.
Resorption assays. Collagen degradation was assessed using the OsteolyseTM Assay Kit (Lonza) following 
the manufacturer’s instructions. Cells were plated on the OsteolyseTM plate and collagen degradation assayed by 
combining 10 μ l of supernatant with 200 μ l of Fluorophore Releasing Reagent. Fluorescence was measured over 
400 μ s with an initial delay of 400 μ s (excitation at 340 nm, emission at 615 nm).
MiRNA profiling. Total RNA was isolated at 0, 3, 6 and 12 days of differentiation using the miRNeasy micro 
kit (Qiagen) following manufacturer’s instructions. RNA integrity was assessed using the Nanodrop (Thermo 
Scientific) and 2100 Bioanalyzer (Agilent). MiRNA expression was performed by Exiqon Services using 
7th generation microarrays (miRBase v.19). 225 nanograms of total RNA were labeled using the miRCURY 
LNATM microRNA Hi-Power Labeling Kit Hy3TM/HY5TM and subsequently hybridized onto miRCURY LNATM 
microRNA Arrays following the procedures described by the manufacturer. Data normalization was performed 
by Exiqon using Quantile normalization. Initial analysis was performed using R/bioconductor primarily using the 
limma package (Exiqon). Expression analysis of variance over time was performed with p values adjusted using 
the Benjamini Hochberg method and identified genes subjected to the Turkey’s ‘Honest Significant Difference’ 
test. Array data was in compliance with MIAME guidelines and deposited in the Gene Expression Omnibus 
(GEO) public database under the accession number GSE60840.
Bioinformatic Analysis. Bioinformatic analysis was performed on miRNAs identified as significantly 
(FDR < 0.05), differentially expressed during monocyte-to-OC differentiation. Of these, only the miRNAs whose 
altered level of expression was maintained (> 72 hrs from initial time-point with significance [FDR > 0.05]) were 
selected for further analysis. We employed miRWalk to predict the candidate 3′ -UTR of genes for miRNA binding 
sites with the 5 established miRNA-target prediction algorithms22. MiRNAs that possessed no predicted tar-
gets linked to regulation of OC differentiation and function by Gene Ontology (GO) biological terms (http://
www.geneontology.org) were not considered. The remaining miRNAs were then ranked according to the sum 
of predicted targets, with each predicted target being given a value of 1. Identification of the target by multiple 
algorithms resulted in a value equal to the number of predictive algorithms (i.e. if the same target was identified 
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by 3 of the 5 algorithms then it was given the value of 3). The top-ranked miRNAs were selected for further inves-
tigation and functional analysis.
RT-PCR analysis. Five hundred nanograms of total RNA was used for first strand cDNA synthesis using 
the miScript RT II kit (Qiagen) according to the manufacturer’s instructions. Expression profiles of miR-223, 
miR-34a-5p and miR-142-3p were examined by miScript PCR assays and SYBR Green Master Mix (both from 
Qiagen). Real-time PCR was performed on a StepOne 7500 thermocycler (Applied Biosystems). Expression lev-
els were normalized with respect to RNU6 (Qiagen). PKCα mRNA levels were analyzed using a StepOnePlus 
Real-Time PCR System (Applied Biosciences). Expression levels were normalized with respect to GAPDH.
Transient miRNA/siRNA transfection. MirScript miRNA 142-3p mimic and inhibitor were purchased 
from Qiagen. AllStars negative mimic (Qiagen) was used as control. Gene specific and control siRNA for PKCα 
knockdown were purchased from Sigma-Aldrich. Transient transfections were performed using Lipofectamine 
2000 (Life Technologies) according to manufacturer’s instructions. Cells were transfected with mimics or inhib-
itors at a final concentration of 100 nM. Red siGLO oligonucleotides (Thermo Fisher Scientific) were used to 
determine transfection efficiency (S2 Table). Viability was assessed by flow cytometry (S3 Table).
Western blots. Cells were lysed in cell lysis buffer (Cell Signaling Technology) supplemented with protease 
inhibitors (Roche). Protein content was estimated using the Bradford assay (BioRad Laboratories). Equal amounts 
of protein were resolved in 10% Mini-PROTEAN® TGX™ (BioRad) gels and electrotransferred to nitrocellulose 
membranes (GE Healthcare). Membranes were blocked with 5% skimmed milk for 2 hrs and incubated with pri-
mary antibodies against PKCα or GAPDH (1:1000; BD Biosciences) overnight at 4 C. The blots were washed with 
PBS 0.1% Tween20 thrice before incubating with secondary antibody (1:10,000) for 1 hr at room temperature. 
Blots were washed with PBS 0.1% Tween20 thrice and protein detection was performed using enhanced chemi-
luminescence (GE Healthcare). ImageJ software (http://rsbweb.nih.gov/ij/) was used to quantify the results. The 
values for each lane were normalized with respect to endogenous control GAPDH.
Viability assays. Cell viability was determined using the CellTiter® 96 AQueous Cell Proliferation Assay Kit 
(Promega) according to manufacturer’s instructions. In brief, 20 μ l of reagent was added to each well of a 96-well 
plate containing OC and 200 μ l of culture medium, incubated for a further 2 hrs, and absorbance at 490 nm was 
recorded using an ELISA plate reader. In certain experiments viability was also quantified by flow cytometry 
using the LIVE/DEAD® Fixable Violet Dead Cell staining kit (Invitrogen).
Statistical Analysis. For miRNA expression, p values were calculated by ANOVA. P values were adjusted 
using the Benjamini Hochberg method. In brief, p values were sorted and ranked (smallest value = 1, second 
smallest = 2, largest = N), each p value was multiplied by N and then divided by its assigned rank to give the 
adjusted p values (FDR). MiRNAs with FDR < 0.05 were considered significant. For ELISA and CellTiter 96® 
AQueous One Solution data, p values were calculated using the Student’s t-test. Statistical analysis of data was 
performed using GraphPad Prism software (GraphPad Software, Inc.). Results are presented as mean + standard 
deviation (SD) or ± SEM from 3 or more biological donors. Data from each individual donor is the mean of 2 
technical replicates. A p value of < 0.05 is considered statistically significant.
Ethical Statement. All methods were performed in accordance with approved guidelines. The study and all 
experimental protocols were approved bythe University of Illinois Institutional Review Board. Informed consent 
was provided by all subjects prior to participating in the study.
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